Eton Pharmaceuticals, Inc. revenue
Eton Pharmaceuticals, Inc.'s revenue was $80.0m in fiscal 2025, up 104.9% on the year before. Since fiscal 2019 ($959,000) it has grown at a compound 109.0% a year. Over the last twelve months it was $106m.
Revenue history
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 0 | 22 | 21 | 32 | 39 | 80 | 106 |
| Growth on the year before | — | −95.9% | +>999% | −2.7% | +48.9% | +23.3% | +104.9% | — |
| Gross profit | 1 | −0 | 19 | 14 | 21 | 23 | 43 | 61 |
| Gross margin | 52.8% | — | 87.1% | 67.4% | 66.6% | 60.0% | 53.5% | 57.9% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Product Sales and Royalties | $76.7M | 95.9% | ▲ 99.1% |
| Licenses | $3.3M | 4.1% | ▲ 557.2% |
From Eton Pharmaceuticals, Inc.'s 10-K filed March 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Eton Pharmaceuticals, Inc. | $106m | 81.5% | 53.8% |
| Niagen Bioscience, Inc. | $129m | 11.0% | 16.8% |
| Zevra Therapeutics, Inc. | $136m | 119.4% | 101.9% |
| Natural Alternatives International Inc | $143m | 9.7% | -2.6% |
| Heron Therapeutics, Inc. | $151m | 1.0% | 8.6% |
| Rockwell Medical, Inc. | $69.4m | -21.1% | -2.9% |
Compare with peers
- Niagen Bioscience, Inc. revenue
- Zevra Therapeutics, Inc. revenue
- Natural Alternatives International Inc revenue
- Heron Therapeutics, Inc. revenue
- Rockwell Medical, Inc. revenue
Head to head: ETON vs NAGEETON vs ZVRAETON vs NAII
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies